Two-Year Follow-Up Outcomes of Premature Infants Enrolled in the Phase I Trial of Mesenchymal Stem Cells Transplantation for Bronchopulmonary Dysplasia
OPEN The Journal of pediatrics | 28 Mar 2017
SY Ahn, YS Chang, JH Kim, SI Sung and WS Park
To determine the long-term safety and outcomes of mesenchymal stem cells (MSCs) for bronchopulmonary dysplasia in premature infants enrolled in a previous phase I clinical trial up to 2 years of corrected age (CA).
* Data courtesy of Altmetric.com